Showing 4711-4720 of 20472 results for "".
- Pharmacal Recalls MG217 Eczema Cream Lot Over Staph Contaminationhttps://reachmd.com/news/pharmacal-recalls-mg217-eczema-cream-lot-over-staph-contamination/2487116/Pharmacal has issued a nationwide consumer-level recall of 1 lot of MG217 Multi-symptom Treatment Cream & Skin Protectant Eczema Cream, 6-oz tube, after the product was found to be contaminated with Staphylococcus aureus, according to a company announcement pos
- Measure Up Data Support Long-Term Laboratory Safety With Upadacitinib in Atopic Dermatitishttps://reachmd.com/news/measure-up-data-support-long-term-laboratory-safety-with-upadacitinib-in-atopic-dermatitis/2487114/Most laboratory parameters remained within normal limits through 140 weeks of upadacitinib treatment in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to findings presented at the 2026 Society for Investigative Dermatology Annual
- Global Skin Cancer Burden Projected to Rise Through 2050: Studyhttps://reachmd.com/news/global-skin-cancer-burden-projected-to-rise-through-2050/2487086/A new research letter published online in JAMA Dermatology highlights widening global disparities in skin cancer burden and projects continued increases in melanoma, cutaneous squamous cell carcinoma (cSCC), and basal cell c
- Amifampridine Fails to Beat Placebo in AChR-Positive MGhttps://reachmd.com/news/amifampridine-fails-to-beat-placebo-in-achr-positive-mg/2487085/Key Takeaways Neither the 30-mg nor the 60-mg regimen was associated with a significant MGII improvement versus placebo. No statistically significant association was observed between pharmacokinetic parameters and MGII. Adverse events were mor
- DELFI to Share Clinical Utility Data at ATS 2026https://reachmd.com/news/delfi-clinical-utility-data-ats-2026/2487067/Key Takeaways DELFI's ATS program centers on the late-breaking FIRSTLUNG presentation, the first interventional study designed to evaluate the clinical utility of a blood-based test in the lung cancer screening pathway. Other presentations will focus o
- Real-World Use of a 1021-Gene Liquid Biopsy Assayhttps://reachmd.com/news/1021-gene-liquid-biopsy-assay/2487065/Key Takeaways A 1021-gene liquid biopsy assay identified at least one on-label actionable biomarker in 16.18% of patients with metastatic cancer. Among 145 paired plasma and tissue cases, concordance for actionable on-label candidates was 90.34%.
- Benralizumab Cuts Flares in Phase 3 Hypereosinophilic Syndrome Trialhttps://reachmd.com/news/benralizumab-phase-3-hypereosinophilic-syndrome/2487074/Key Takeaways Benralizumab was associated with fewer HES flares and lower relapse measures than placebo during the 24-week double-blind period. Near-complete blood eosinophil depletion and fewer corticosteroid dose increases were observed with benraliz
- Evaluating Lenacapavir and bNAbs in HIV-1https://reachmd.com/news/lenacapavir-bnabs-hiv-1/2487075/Key Takeaways Week-26 virologic control was broadly similar between a long-acting regimen and continued oral ART in this phase 2 comparison. Adverse-event rates were broadly comparable after excluding injection-site reactions, and no serious adverse ev
- Avalyn Announces ATS 2026 Presentations on Ap01 Delivery and Supportive Carehttps://reachmd.com/news/avalyn-ats-ap01-supportive-care/2487070/Key Takeaways Avalyn plans to present two ATS 2026 posters covering AP01 delivery usability and supportive healthcare experiences in idiopathic pulmonary fibrosis. The AP01 poster is a usability study of the eFlow Nebulizer System, with feedback from p
- LaserAway Marks 20 Years with Continued National Expansionhttps://reachmd.com/news/laseraway-marks-20-years-with-continued-national-expansion/2487069/LaserAway is celebrating its 20th anniversary alongside continued national expansion and recent recognition within the aesthetics industry. The company, which specializes in aesthetic dermatology services, announced that it now operates more than 215 clinics across the United States. The c